N@N

SCMP, DSCI, TWER, HCKT, OXBT, AVNR Are Seasonally Ripe To Go Down In the Next Five Weeks

September 12, 2012 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Sucampo Pharmaceuticals Inc (NASDAQ:SCMP), Derma Sciences Inc (NASDAQ:DSCI), Towerstream Corp (NASDAQ:TWER), HACKETT GROUP INCORPORATION.(THE) (NASDAQ:HCKT), Oxygen Biotherapeutics Inc (NASDAQ:OXBT), Avanir Pharmaceuticals Inc (NASDAQ:AVNR) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Down:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  SCMP    Sucampo Pharmaceuticals Inc      -3.78%           100.00% (5 of 5)     Tuesday, September 18th 2012
  DSCI    Derma Sciences Inc               -11.89%          88.89% (8 of 9)      Wednesday, October 10th 2012
  TWER    Towerstream Corp                 -6.46%           100.00% (5 of 5)     Thursday, September 20th 2012
  HCKT    HACKETT GROUP INCORPORATION.(THE)  -7.97%           81.82% (9 of 11)     Tuesday, October 2nd 2012
  OXBT    Oxygen Biotherapeutics Inc       -14.47%          90.91% (10 of 11)    Thursday, October 4th 2012
  AVNR    Avanir Pharmaceuticals Inc       -4.55%           90.91% (10 of 11)    Friday, September 14th 2012

Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) - Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs based on prostones primarily in the Americas, Europe, and Asia. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of open-angle glaucoma and ocular hypertension. In addition, the company is developing Amitiza for the treatment of opioid-induced bowel dysfunction, which completed two Phase III clinical trials; Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers, which completed a Phase IIa clinical trial; SPI-017, a Phase I clinical trial product, for the treatment of Peripheral arterial disease; and SPI-3608 for the treatment of spinal stenosis, which is under preclinical trial. Additionally, it is conducting a preclinical trial of Rescula for dry age related macular degeneration; and preclinical trials of Cobiprostone for the treatment of chronic obstructive pulmonary disease and wound healing. Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Derma Sciences Inc (NASDAQ:DSCI) - Derma Sciences, Inc. engages in manufacturing, marketing, and selling wound care, wound closure and specialty securement devices, and skin care products. The company offers advanced/active wound care products comprising Medihoney dressings to manage non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; Bioguard dressings for prophylactic use to prevent hospital or community acquired infections through wound sites; Algicell Ag, an antimicrobial dressing; Xtrasorb dressings that convert fluid within the dressing to a gel and locks the exudates into the dressing; TCC-EZ, a dressing system for the management of diabetic foot ulcers; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and Dermagran products. It also provides traditional wound care products, such as gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices, as well as adhesive bandages and related first aid products for the medical, industrial, private label, and retail markets. In addition, the company offers wound closure strips, nasal tube fasteners, and catheter fasteners to doctors, clinics, nursing homes, hospitals, and other institutions; and barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils, and moisturizers to nursing homes, hospitals, and home healthcare agencies. Further, it involves in developing DSC127, an angiotensin analog for use in wound healing and scar reduction. The company serves wound care centers, long-term care facilities, hospitals, home healthcare agencies, physicians offices, and closed door pharmacies. It sells its products primarily through independent distributors in the United States, Canada, and internationally. The company was founded in 1984 and is headquartered in Princeton, New Jersey.

Towerstream Corp (NASDAQ:TWER) - Towerstream Corporation, through its subsidiaries, provides broadband services to commercial customers and delivers access over a wireless network transmitting over both regulated and unregulated radio spectrum. Its service supports bandwidth on demand, wireless redundancy, virtual private networks (VPNs), disaster recovery, bundled data, and video services. The company offers service to approximately 1,900 business customers in New York City, Boston, Chicago, Los Angeles, San Francisco, Seattle, Miami, Dallas-Fort Worth, Philadelphia, Providence, and Newport, Rhode Island. Towerstream Corporation offers its services indirectly through various authorized representatives, such as integrators, resellers, and online operators. The company was founded in 1999 and is based in Middletown, Rhode Island.

HACKETT GROUP INCORPORATION.(THE) (NASDAQ:HCKT) - The Hackett Group, Inc. operates as a strategic advisory and technology consulting firm primarily in the United States and western Europe. The company offers executive advisory programs, benchmarking, business transformation, and technology consulting services, as well as shared services, offshoring services, and outsourcing advices. Its executive advisory programs consist of advisor inquiry, an inquiry service used by clients for access to fact-based advice on proven approaches and methods to increase the effectiveness of selling, general, and administrative processes (SG&A); best practice research, a research that provides insights into the proven approaches in use at organizations; peer interaction program comprising member-led Webcasts, annual practice conferences, annual member forums, membership performance surveys, and client-submitted content; and best practice intelligence center, an online, searchable repository of practices, performance metrics, conference presentations, and associated research. The companys bench marking services conduct studies in the areas of SG&A, finance, human resources, information technology, procurement, enterprise performance management, shared service centers, and working capital management. These services are used by clients to establish priorities, generate organizational consensus, align compensation to establish performance goals, and develop the required business case for business and technology investments. Its business transformation programs help clients to develop coordinated strategy for achieving performance improvements across the enterprise; and Hackett Technology Solutions, which help clients choose and deploy the software applications that meet their needs and objectives. The company was formerly known as Answerthink, Inc. and changed its name to The Hackett Group, Inc. in January 2008. The Hackett Group, Inc. was founded in 1991 and is based in Miami, Florida.

Oxygen Biotherapeutics Inc (NASDAQ:OXBT) - Oxygen Biotherapeutics, Inc. develops medical and cosmetic products that deliver oxygen to tissues in the body. It develops a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte that is being formulated for both intravenous and topical delivery for conditions, including but not limited to traumatic brain injury, decompression sickness, cosmetics, and topical wounds. The companys under development product include Vitavent, an oxygen exchange fluid for facilitating the treatment of lung conditions. In addition, it out-licensed its rights to a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid. Further, Oxygen Biotherapeutics offers Dermacyte line of oxygen-rich skin care products that promote the appearance of skin health and other desirable cosmetic benefits; and Wundecyte, a wound-healing gel. The company markets and sells Dermacyte line of products through www.buydermacyte.com; and to dermatologists and medical spas with a combination of in-house sales and exclusive distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its name to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics was founded in 1967 and is based in Durham, North Carolina.

Avanir Pharmaceuticals Inc (NASDAQ:AVNR) - AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. Its lead product candidate includes Zenviatm, which has completed three Phase III clinical trials for the treatment of pseudobulbar affect; and a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. The company also offers Abreva, an over-the-counter product for the treatment of cold sores. AVANIR Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641